Cowen raises Ultragenyx price target to $19 from $18, cites 2027 expense reduction plan

Cowen raised its price target on Ultragenyx to $19 from $18 after a slight Q3 revenue miss of $173M (Crysvita $109M, Doljovi $30M) versus consensus of $177M. Management reiterated 2026 guidance but plans significant 2027 expense reduction from R&D and a 20% workforce cut, with 2027 profitability guidance.

Detected & updated continuously · Source: Nebula